Pfizer's hemophilia B gene therapy succeeds in late-stage study

Pfizer's hemophilia B gene therapy succeeds in late-stage study

US drugmaker Pfizer said on Thursday (Dec 29) its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal in a late-stage study. Data from the study showed that a single dose of the therapy was superior to the current standard of care in helping reduc

Pfizer’s haemophilia B gene therapy succeeds in late-stage study

Haemophilia B is an inherited disorder hampers the body's ability to make a blood-clotting protein called factor IX.

Pfizer haemophilia gene therapy hits goal in final-stage study

Results may allow pharma giant to compete with treatment approved in US last month

Pfizer says hemophilia B gene therapy met key goal in Phase 3 trial

JHVEPhoto Pfizer (NYSE:PFE) announced Thursday that the company’s investigational gene therapy for hemophilia B, fidanacogene elaparvovec, met the primary endpoint in a Phase 3 trial called BENEGENE-2 involving adults males… This News Pfizer says hemophilia B gene therapy met key goal in Phase 3 trial appeared first on STL.News.

Pfizer’s hemophilia B gene therapy succeeds in late-stage study

(Reuters) - U.S. drugmaker Pfizer Inc said on Thursday its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal in a late-stage study. Data from the study showed that a single dose of the therapy was superior to the current standard of care in helping reduce the bleeding rate in patients with moderately severe to severe forms of hemophilia B. The disorder hampers the body's ability t…

Pfizer says hemophilia B gene therapy significantly reduces bleeds

Pfizer's trial results come a month after UniQure's treatment was approved as the first gene therapy for hemophilia B.